FDA Accepts Supplement for Buprenorphine/Naloxone from Ascent Pharmaceuticals
The FDA has accepted the supplemental application ANDA219727 for Buprenorphine Hydrochloride and Naloxone Hydrochloride submitted by Ascent Pharmaceuticals.
Company
Pharmaceutical intelligence for Ascent Pharmaceuticals with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.